NE-3107 Alzheimer's, Parkinson's data boost Biovie
By A Mystery Man Writer
Description
Alzheimer's Innovations, Alzheimer's Disease Research
Spintech's neurological software gets boost with $6.5M in series A financing
Neurology/psychiatric
Noninvasix breathes easier with breakthrough device designation
BioVie Announces Additional Findings from Phase 2 Alzheimer's Disease Trial: NE3107 Appears to Impact Biomarkers of Aging-Related Disease States in Addition to Observed Reversal of Cognitive Decline in Dementia
ATN-161 ameliorates neuroinflammation and BBB permeability in vascular dementia
Intercept heads for FDA talks to 'Regenerate' filing for NASH hopeful obeticholic acid
subjective cognitive decline
BioVie (BIVI): Treating Alzheimer's, Parkinson's, Reversing The Biological Clock
New compound
BioVie Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer's Disease
Novel hybrid molecules for the management of Parkinson's disease disclosed
BioVie Announces EfficacyData from Phase 3 Trial of NE3107 in Patientswith Mild to Moderate Alzheimer's Disease
Machine learning sleuthing yields undiagnosed binge eating patients, insights
from
per adult (price varies by group size)